

**Lista de lucrări**  
**Pentru posturile de cercetare**  
**Candidat: Kubelac Milan-Paul**  
**10.01.2024**

**Teza de doctorat**

Perspective evoluționiste în cancerul ovarian. Sustinută la data de 25.03.2022. Titlu de doctor în domeniul Medicină obținut în baza Ordinului Ministrului Educației nr. 3981 din 08.06.2022.

**Cărți publicate**

1. Alexandra-Cristina Bot, Dana-Ioana Iancu, Milan-Paul Kubelac, Nicolae Todor, Patriciu Achimas-Cadariu, Tudor-Eliade Ciuleanu (Ed.). Compendiu de Oncologie Medicală: principii și practică. Cluj: Casa Cărții de Știință, 2021.
2. Achimas Cadariu P, Kubelac P, Irimie Alexandru. Mezoteliomul peritoneal malign. In Grigorescu M, Irimie A, Beuran M (Ed.), Tratat de oncologie digestivă, vol. III. București: Editura Academiei Române, 2015.
3. Liseicu C, Achimas Cadariu P, Kubelac P, Irimie A. Cancerul rectului - Tratamentul chirurgical în boala locală și locoregională. In Grigorescu M, Irimie A, Beuran M (Ed.), Tratat de oncologie digestivă, vol. III. București: Editura Academiei Române, 2015.
4. Achimas Cadariu P, Lisencu C, Petrut B (Ed.), Compendiu de Oncoginecologie în scheme și imagini. Cluj: Editura Medicala Universitară "Iuliu Hatieganu" Cluj-Napoca, 2015.

**Articole/ studii publicate în reviste de specialitate de circulație internațională recunoscute sau în reviste din țară recunoscute de către CNCSIS**

1. Roman A, Brozba A, Necula A, Muntean DD, Kubelac P, Fekete Z, et al. Usefulness of Saline Sealing in Preventing Pneumothorax after CT-Guided Biopsies of the Lung. *Diagnostics* (Basel). 2023;13(23).
2. Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim D, Lim S, Martin E, Frenel JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. *Front Oncol.* 2023 Jan 27;13:1114435.
3. Yordanov A, Vasileva-Slaveva M, Galai N, Faraggi D, Kubelac MP, Tripac-Iacovleva I, Calleja N, Di Fiore R, Calleja-Agius J. Cancer of the Cervix in Bulgaria: Epidemiology of a Crisis. *Healthcare* (Basel). 2023 Jan 20;11(3):318.
4. Pașca A, Fischer-Fodor E, Monica Jiboc N, Milan Kubelac P, Saha B, Vlad C, Andrei Achimaș-Cadariu P. Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. *Cytokine.* 2023 Jan;161:156073.
5. Leskovská J, Miklášová N, Kubelac PM, Achimaș-Cadariu P, Valentová J, Markuliak M, Fischer-Fodor E. Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-κB Transcription Factor, FGF-2 Growth Factor, and MMP-9 Pathway. *Molecules.* 2022 Jul 18;27(14):4565.
6. Preda A, Ciuleanu T, Kubelac P, Todor N, Balacescu O, Achimas-Cadariu P, Iancu D, Mocan C, Bandi-Vasilica M, Lupse M, Briciu VT, Man MA, Vlad C. Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuta Oncology Institute series. *Esmo Open.* 2022;7(2).
7. Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Ruhli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. *J Ovarian Res.* 2022;15(1):67.

8. Yordanov A, Kostov S, Slavchev S, Strashilov S, Konsoulova A, Calleja-Agius J, Di Fiore R, Suleiman S, Kubelac P, Vlad C, Achimas-Cadariu P, Vasileva-Slaveva M. Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management. *Cancer Management and Research*. 2021;13:4979-86.
9. Vlad HS, Florea M, Nucu AM, Vlad IC, Cojocaru I, Vlad M, Kubelac P, Borz MB. 3D laparoscopic salvage radical prostatectomy: mini-series report and review of the literature. *Journal of Buon*. 2021;26(3):964-9.
10. Kubelac P, Braicu C, Raduly L, Chiroi P, Nutu A, Cojocneanu R, Budisan L, Berindan-Neagoe I, Achimas-Cadariu P. Comprehensive Analysis of the Expression of Key Genes Related to Hippo Signaling and Their Prognosis Impact in Ovarian Cancer. *Diagnostics*. 2021;11(2).
11. Gaia-Oltean AI, Pop LA, Cojocneanu RM, Buse M, Zimta AA, Kubelac P, Irimie A, Coza OF, Roman H, Berindan-Neagoe I. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. *American Journal of Cancer Research*. 2021;11(4):1754-69.
12. Di Fiore R, Suleiman S, Ellul B, O'Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimas-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors-Current Challenges and Future Directions. *Cancers*. 2021;13(3).
13. Bonci EA, Titu S, Petrusan AM, Hossu C, Gata VA, Ghomi MT, Kubelac PM, Bonci TI, Piciu A, Cosnarovici M, Hitu L, Kirsch-Mangu AT, Pop DC, Lisencu IC, Achimas-Cadariu P, Piciu D, Schmidt H, Fetica B. Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis. *Medicina-Lithuania*. 2021;57(3).
14. Rusu CB, Bujoreanu CE, Irimie A, Achimas-Cadariu P, Vlad C, Kubelac P, Hardo VV, Maghiar TT, Maris CV, Idris Y, Petrut B. Totally intracorporeal 3D laparoscopic orthotopic neobladder reconstruction following radical cystectomy for infiltrative bladder tumors: the experience of modified Studer and modified Y-shaped ileal reconstruction techniques. *Journal of Buon*. 2020;25(1):286-94.
15. Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. *Cancers*. 2020;12(3).
16. Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, Lisencu C, Rancea A, Vlad C, Irimie A, Achimas-Cadariu P. Institutional results of OncoOVARIAN Dx - a novel algorithm for the preoperative evaluation of adnexal masses. *Journal of Buon*. 2020;25(3):1658-63.
17. Gata VA, Kubelac PM, Buiga R, Vlad IC, Valean D, Muntean MV, Morariu DS, Bonci EA, Irimie A, Dina C, Achimas-Cadariu PA. The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma. *Journal of Buon*. 2020;25(6):2700-7.
18. Moisoiu V, Stefancu A, Gulei D, Boitor R, Magdo L, Raduly L, Pasca S, Kubelac P, Mehterov N, Chis V, Simon M, Muresan M, Irimie AI, Baciut M, Stiufluc R, Pavel IE, Achimas-Cadariu P, Ionescu C, Lazar V, Sarafian V, Notinger I, Leopold N, Berindan-Neagoe I. SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer. *Int J Nanomedicine*. 2019;14:6165-78.
19. Kubelac P, Vlad C, Berindan-Neagoe I, Irimie A, Achimas-Cadariu P. The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients. *Journal of Buon*. 2019;24(4):1538-43.
20. Vlad C, Dina C, Kubelac P, Vlad D, Pop B, Achimas-Cadariu P. Expression of toll-like receptors in ovarian cancer. *Journal of Buon*. 2018;23(6):1725-31.

21. Achimas-Cadariu P, Iancu M, Kubelac P, Pop F, Braicu I, Vlad C, Oskay-Ozcelik G, Sehouli J. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III. *Eur J Cancer Care (Engl)*. 2017;26(6).
22. Vlad C, Kubelac P, Onisim A, Fetica B, Fulop A, Irimie A, Achimas-Cadariu P. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment. *Journal of Buon*. 2016;21(4):973-8.
23. Onisim A, Iancu M, Vlad C, Kubelac P, Fetica B, Fulop A, Achimas-Cadariu A, Achimas-Cadariu P. Expression of Nestin and CD133 in serous ovarian carcinoma. *Journal of Buon*. 2016;21(5):1168-75.
24. Vlad C, Kubelac P, Vlad D, Irimie A, Cadariu PA. Evaluation of clinical, morphopathological and therapeutic prognostic factors in rectal cancer. Experience of a tertiary oncology center. *Journal of Buon*. 2015;20(1):92-9.
25. Vlad C, Kubelac P, Onisim A, Irimie A, Achimas-Cadariu P. The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer. *Journal of Buon*. 2015;20(3):673-9.
26. Vlad C, Kubelac P, Fetica B, Vlad D, Irimie A, Achimas-Cadariu P. The prognostic value of FOXP3(+) T regulatory cells in colorectal cancer. *Journal of Buon*. 2015;20(1):114-9.
27. Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P. Current insights into the association of Nestin with tumor angiogenesis. *Journal of Buon*. 2015;20(3):699-706.
28. Kubelac MP, Fetica B, Vlad IC, Fulop A, Popa A, Achimas-Cadariu P. The Role of Inhibitor of DNA-binding 1 (ID-1) Protein and Angiogenesis in Serous Ovarian Cancer. *Anticancer Res*. 2014;34(1A):413-6.

**Studii publicate în volumele unor manifestări științifice internaționale recunoscute din țară și din străinătate (cu ISSN sau ISBN)**

1. Pasca A, Paun DL, Kubelac PM, Gata VA, Jiboc NM, Vlad CI, et al. #1004 Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A362-A.
2. Kubelac P, Avram A, Turcas A, Roman A, Piciu A, Pasca A, et al. #746 Molecular analysis of BRCA and hrD status from small biopsies in high grade serous carcinoma. a real-world comparative analysis. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A306-A7.
3. Frenel J-S, Guerin-Charbonnel C, Xu-Vuillard A, Cheeseman S, Kubelac P, Zenatri M, et al. #201 Real world evidence (RWE) on the efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer. a multicentre, international study. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A257-A.
4. Irina T, Valentina S, Valeriu T, Victor S, Jean CA, Mariela V-S, et al. #103 Epigenetic silencing of MLH1 as a prognostic factor for endometrial cancer recurrence. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A131-A2.
5. Kubelac P. Treatment of ovarian sex cord stromal and germ cell tumours. *Int J Gynecol Cancer*. 2022;32:10-.
6. Kubelac P, Catalin V, Pasca A, et al 2022-RA-1405-ESGO Indocyanine green in near-infrared light for intra-operative imaging of residual ovarian cancer after neoadjuvant chemotherapy. Initial experience. *International Journal of Gynecologic Cancer* 2022;32:A333.
7. Pasca A, Fischer-Fodor E, Jiboc NM, Kubelac PM et al 2022-RA-437-ESGO Meta-analyses reveal serum or plasma interleukin-6 as a biomarker for malignant ovarian neoplasia *International Journal of Gynecologic Cancer* 2022;32:A233-A234.

8. Kubelac MP, Vlad C, Pop B, Fetica B, Fischer-Fodor E, Soritau O, Balacescu O, Ignat F, Lazar G, Lisencu C, Rancea A, Irimie A, Achimas-Cadariu P. Perioperative dynamic evaluation of folate receptor alpha expression in ovarian carcinoma. *Int J Gynecol Cancer*. 2021;31:A207-A8.
9. Woopen H, Keller M, Braicu I, Zocholl D, Baum J, Krabisch P, Boxler T, Wimberger P, Madronal C, Gil-Martin M, Bjelic-Radisic V, Trpchevski S, Samartzis EP, Heinzelmann-Schwarz VA, Achimas-Cadariu P, Kubelac P, Vardar MA, Jedryka MA, Vergote I, Sehouli J. Health concerns in long-term survivors with ovarian cancer: Results of Expression VI-Carolin meets HANNA-Holistic Analysis of Long-term survival with Ovarian Cancer-The international NOGGO, ENGOT and GCIG survey. *J Clin Oncol*. 2021;39(15).
10. Hall G, Cheeseman S, Levick B, Nam EJ, Lim S, Classe JM, Martin E, Kubelac P, Achimas-Cadariu P, Savva-Bordalo J, Borges M, Becker S, Shaid S, Niklas N, Guergova-Kuras M. An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes. *J Clin Oncol*. 2021;39(15).
11. Levick B, Cheeseman S, Nam EJ, Doh H, Lim S, Kim D, Bocquet F, Martin E, Kubelac P, Achimas-Cadariu P, Calisto R, Magalhaes M, Becker S, Wolf A, Niklas N, Guergova-Kuras M, Hall G. OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling-The use of a common data model and shared analytical methods. *J Clin Oncol*. 2021;39(15).
12. Cheeseman S, Levick B, Nam E, Lim S, Rouzier R, Bonneau C, Kubelac MP, Achimas-Cadariu PA, Classe JM, Bocquet F, Becker S, Guergova-Kuras M, Hall G. Real world retrospective study of patients with epithelial ovarian cancer: an international comparison. *Int J Gynecol Cancer*. 2020;30:A75-A6.
13. Kubelac P, Craciun AM, Jalba O, Lazar G, Ignat FL, Lisencu IC, et al. Institutional results of oncoovarian dx: a novel algorithm for the management of adnexal masses. *International Journal of Gynecological Cancer*. 2019;29:A427-A.
14. Kubelac P, Auguste A, Genestie C, Mesnage S, Le Formal A, Achimas-Cadariu P, et al. Changes in DNA damage response markers with treatment in advanced ovarian cancer. *Gynecologic Oncology*. 2018;149:164-5.

#### **Proiecte de cercetare-dezvoltare-inovare pe bază de contract/ grant**

1. TRANSCAN-3 Next generation cancer immunotherapy: Targeting the tumour Microenvironment nr. 319 / 2022 Cod proiect:ERANET-TRANSCAN-3-TANGERINE Grant Member 2022-2025
2. Modularea metalomica a transportorilor membranari in celulele tumorale ovariene chimiorezistente cu ajutorul nano-sensibilizatorilor PN-III-P4-PCE2021-1572 Grant Member 2022-2024
3. European network for Gynaecological Rare Cancer research: From Concept to Cure COST Action CA18117 Management Committee Substitute 2019-2023
4. Addressing the complex exposome profile in hormone-dependent cancers of the breast and prostate and its influence on tumoral genome PN-III-P4-ID-PCE-2016-0795 Grant Member 2019
5. Complex frontier research project: New Targeted Optical Imaging NanoProbes for Near-Infrared (NIR) Real-Time (RT)Image-Guided Surgery of Ovarian Cancer. Babes Bolyai University and Prof. Dr. I.Chiricuta Oncology Institute Cluj-Napoca PN-III-P4-ID-PCCF-2016-0142 Grant Member 2018-2022

6. Intelligent system for evaluation of ovarian cancer risk PN-III-P2- Grant 2018  
2.1-CI-2018-1509. Prof. Dr. I. Chiricuta Oncology Institute Cluj- Member Napoca
7. PhD Research Grant 3066/29/01.02.2018 Grant 2016-2020  
“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj- Director Napoca, Romania
8. Transfer de cunoștințe în aplicații clinice ale biogenomicii în Grant 2017  
oncologie și domenii conexe” BIOGENONCO, ID P\_40\_31 Member  
“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj- Napoca, Romania
9. Students’ Research Grant 22714/22/06.10.2011 Grant 2011-2012  
“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj- Director Napoca, Romania